Ring Therapeutics, a pioneering life sciences company under Flagship Pioneering dedicated to reshaping gene therapy through its unique commensal virome platform, today announced transformative new partnerships with the Agency for Science, Technology, and Research (A*STAR), Singapore’s premier public research institution, and the Singapore Eye Research Institute (SERI). These collaborations are set to accelerate groundbreaking research and foster advancements in ophthalmology, oncology, and bioprocessing technologies critical to the production of innovative therapeutics.

Dr. Tuyen Ong, CEO of Ring Therapeutics and CEO-Partner at Flagship Pioneering, underscored the strategic impact of these alliances: “The value of these partnerships extends across our entire platform—from the early discovery phase, where we are poised to map novel anellovirus genomes for ophthalmic and oncological applications, to testing new therapeutic payloads and refining our cutting-edge manufacturing processes. By integrating with a global network of R&D leaders, these collaborations will advance the clinical translation of our AnelloVector™ therapeutics and deepen the reach of our Anellogy platform.”

The partnership is designed to expedite the development of innovative treatments for eye diseases and cancer, while optimizing bioprocessing techniques to ensure scalable production. By combining A*STAR’s extensive research prowess and SERI’s specialized expertise in ophthalmic gene therapy, this initiative will amplify Singapore’s status as a hub for biomedical excellence.

Driving Scientific and Patient-Centric Outcomes

Professor Tan Sze Wee, Assistant Chief Executive of the Biomedical Research Council at A*STAR, stated: “Partnering with Ring Therapeutics supports our mission to bring forward impactful medicines. Together, we leverage world-class technologies and a shared commitment to translating novel research into patient-ready therapies. This partnership is an important step for advancing biomedical innovation within Singapore’s ecosystem and beyond.”

Professor Jodhbir Mehta, Executive Director of SERI, emphasized the groundbreaking potential in ophthalmic care: “Gene therapy opens doors to address previously untreatable eye conditions. Working alongside Ring Therapeutics, we will explore next-generation viral vectors with enhanced tropism and redosable potential. This collaboration signals a leap forward in creating therapies that can alleviate vision impairment and enhance quality of life.”

A Catalyst for Biotech Evolution

This partnership represents a major stride in fostering a robust and innovative biotech landscape in Singapore, catalyzing discoveries that blend cutting-edge science with practical applications. The combined expertise aims to not only fuel clinical advancements but also inspire broader R&D development that will benefit patients globally.